The story quotes CIRM's Natalie DeWitt:
Few stem cell therapies, with the exception of hematopoietic stem cells derived from bone marrow or cord blood, are currently used in routine medical practice. The proponents of the Alpha clinics hope to lay the groundwork for more. “We're kind of doing this in anticipation of this field really growing,” DeWitt says.Our Governing Board will be voting on the $70 million proposal at their next meeting in Burlingame, CA on July 25. Members of the public are welcome to attend the meeting or listen in to hear the conversation about these clinics. Agenda and dial in information will be on our website.